Post-breast cancer fatigue: it's depression and stress, not cardiac damage

She finished chemotherapy. She finished radiotherapy. The surgical scar has healed. By the clinical metrics of treatment completion, she is done.

And she is exhausted — not in the week-after-chemo way, but in the persistent, year-two, “I’m still not myself” way. She has mentioned it at appointments. The implicit answer she receives is some version of: your body went through a lot, your heart took a hit from the doxorubicin, give it time.

A prospective cohort study published in JAMA Network Open reframes that answer in a way that has direct clinical implications for how GPs approach breast cancer survivorship.

What the study found

The study followed 381 women — 236 with stage I-III breast cancer and 145 controls — from before treatment initiation through assessments at 3 and 24 months. Mean age: 54 years. Treatment groups included doxorubicin-based chemotherapy, non-doxorubicin chemotherapy, and aromatase inhibitors.

Nearly 35% of breast cancer patients had elevated fatigue at 24 months. That figure alone warrants attention — more than one in three women, two years into survivorship, still significantly fatigued.

The expected finding was that cardiac function would explain a meaningful proportion of this. Doxorubicin is cardiotoxic; its effects on left ventricular function are well-documented; it was reasonable to hypothesise that compromised cardiac output would drive persistent fatigue. The study found no association between cardiac function and fatigue at the 24-month mark.

What it found instead: depressive symptoms and perceived stress were independently associated with fatigue at both 3 months and 24 months. Depression carried the stronger signal — approximately three times that of stress. Both factors partially mediated the relationship between cancer treatment and long-term fatigue.

Both-and: the physical and the psychological are not competing explanations

This finding does not mean chemotherapy is not hard on the body. It means that for the specific outcome of fatigue measured at two years, the psychological mediators were doing more work than the cardiac ones — and that the two pathways call for different clinical responses.

A cardiac-mediated fatigue calls for optimising cardiovascular function: cardiac rehabilitation, exercise prescription, managing heart failure if present. A psychologically-mediated fatigue calls for something structurally different: active mental health screening, psychosocial intervention, physical activity (which benefits both pathways), and, where depression is clinically significant, treatment for the depression itself.

The both-and framing here is important. “Psychological mediators” in breast cancer survivorship is not a statement that fatigue is imagined or that the patient’s distress is not real. Depressive symptoms in breast cancer survivors are not a separate condition sitting alongside the cancer — they are a measurable consequence of the total experience: diagnosis, treatment, altered relationships, changed body, the particular grief of a body that has been at war with itself, the weight of survivorship and uncertainty. That depression is real. The fatigue it drives is real. Attributing persistent fatigue solely to treatment toxicity and advising watchful waiting misses where the clinical intervention lives.

The study authors named three response targets with existing trial support: physical activity, psychosocial intervention, and screening for both depression and stress during fatigue assessment. These are available tools, not research horizons.

2 cents

For GPs managing breast cancer survivors: persistent fatigue at the one- or two-year mark is worth explicitly screening for depression and perceived stress — not only anaemia, thyroid function, or cardiac review.

The pivot in the consultation is practical: “Your bloods are fine and your cardiac function looks stable — but I want to ask about mood and stress, because the research is showing that at this stage of survivorship, those are often where the fatigue is actually coming from.” That reframe is not downgrading the symptom or dismissing the physical experience. It is pointing toward where the active clinical work needs to happen.

Where depressive symptoms are present, the conversation extends to whether antidepressant therapy is appropriate — a decision that is often deferred in survivorship because “she’s already been through so much, I don’t want to add another medication.” This study is a reason not to default to deferral. Untreated depression in a breast cancer survivor does not resolve on its own while the cancer treatment is credited with the problem.

Breast cancer survivorship for women in their forties and fifties is a long chapter — potentially decades of managing the aftermath of something that changed their relationship with their own body. Getting the fatigue conversation right at year two is not a minor clinical detail. It is the foundation for quality of life through the years that follow.

Verdict: yes — reframe persistent fatigue in breast cancer survivors toward active psychological screening and intervention, not watchful waiting for treatment effects to resolve.

---

Sources cited

1. Depression, stress may drive long-term fatigue after breast cancer treatment — The Medical Republic
2. Depressive symptoms, perceived stress, and long-term fatigue in breast cancer survivors — JAMA Network Open